Tag Archives: medical device market

Tales from the Road – Arab Health

We’ve just departed from Dubai having completed a very successful Arab Health exposition. The Vasomedical booth included displays, graphics and demonstrations from all segments of our company profile, including EECP® and ECP therapy systems, Biox’ new ECG Holter and ambulatory blood pressure monitors and our wireless MobiCare™ patient monitoring products. Our booth location was ideal, we were in one of the convention center’s main concourses and was extremely busy throughout the whole show. We were joined in the booth by our associates from Biox and VSK, Vasomedical’s newest joint venture for marketing and sales of EECP/ECP technology globally. Together we welcomed many visitors from all over the Middle East, as well as visitors from North America, Europe and India.

This show allowed us to increase our exposure in the Middle East. There are treatment centers in the Kingdom of Saudi Arabia, the United Arab Emirates, Egypt, Jordan, the Sudan, Bahrain, Oman and Israel. Many physicians in the region are familiar with the clinical benefits of the therapy and are very interested in bringing the technology to their local hospitals and clinics.

Biox – MobiCare™ wireless patient monitoring products attracted a high level of interest at the show. The flexibility to un-tether the patient from the monitor using Bluetooth technology is very unique. Along with the added feature of remote viewing capabilities away from the clinical setting by physicians, healthcare workers and patient families, it was evident that MobiCare™ was one of the most interesting new products seen by many of the attendees.

Introducing EECP Therapy to Latin American Healthcare Professionals at FIME 2013

Interest in medical devices, supplies, services and healthcare cost management in Latin America brought tens of thousands of visitors to Miami this week for the Florida International Medical Exposition (FIME), filling the Miami Convention Center and the local South Beach area and hotels.

While most visitors spent their time strolling the aisles full of exhibitors in the convention center, a group of interested medical professionals attended my presentation on the “Effects of Enhanced External Counterpulsation (EECP®) Therapy on Patient Outcomes.”

The presentation and the questions that followed focused not only on the scientifically proven clinical benefits of the Therapy, but on the tremendous potential saving to the healthcare budgets that could be realized in Latin American countries if EECP Therapy was used more often instead of, or as an adjunct to, palliative invasive procedures like stenting and bypass surgery. As in the United States, the expected increase in cardiovascular diseases such as angina and congestive heart failure, already compounded by the current epidemic prevalence of diabetes in Latin America, is unsustainable financially in the future. The need for a more cost-effective treatment to meet the clinical and financial challenges for these and additional cardiovascular diseases can be met more successfully with a greater awareness, adoption and support of EECP Therapy.

I am always happy to do my part in raising awareness about this great treatment, and it didn’t hurt that I got to enjoy sun, sushi and salsa in Miami while I was there!

Uptick of Type 2 Diabetes in Adolescents and Youth – How can we help?

Type 2 diabetes (T2D) has always been referred to as “adult-onset,” and generally considered not to affect adolescents and youth. However, the recent child obesity epidemic has led to an increased incidence of T2D in children and adolescents from 10-19 years of age, as reported in papers and editorial commentaries in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study in the June issue of Diabetes Care.

The most surprising and alarming results of the TODAY study are the fast rate of disease progression of T2D in youth compared to progression in an adult, the high rate of co-morbidities and subsequent complications and the inadequate treatment options for this patient population.

The TODAY study is an ongoing study supported by the National Institute of Health, monitoring more than 500 youth with T2D since 2004. Participants were randomly assigned to one of three treatment groups: metformin alone, metformin plus rosiglitazone, or metformin plus intensive life-style changes. The study found that the rate of deterioration of beta cell function (cells in the body that produce insulin to help transfer glucose into cells) in youth with T2D was four times higher than adults and only the group in the metformin plus rosiglitazone achieved a significant improvement in the preservation of beta function and insulin sensitivity.

Additionally, high blood pressure, kidney disease, body mass composition, eye disease, and cardiovascular risk factors, including lipid and inflammatory markers increased in proportion to the rise in A1C (a protein indicating the severity of T2D) and over time. The development of T2D among youth has significant public health consequences, as the complications of diabetes in kidney, eye and cardiovascular disease will be manifested during the most active and productive periods of their lives.

So what can we do to help address this issue?

For starters, Enhanced External Counterpulsation (EECP®) Therapy can potentially help this cohort of patients by managing the glycemic control in young people. There are published studies in medical journals with data demonstrating that EECP can improve the delivery of glucose to muscle cells where it will be utilized effectively and reduce insulin resistance by activating the glucose transporter which helps insulin transport glucose into cells. Furthermore, there is sufficient evidence showing that EECP can improve endothelial function, producing factors that neutralize oxidative stress and inflammatory markers, while also reducing the co-morbid complications. These complications occur at higher rates in T2D youth because they will have a longer time to endure diabetic complications.

Currently, it is a working hypothesis that EECP Therapy may reduce the deleterious impact diabetes has in the young population and our health care system; additional clinical studies have to be done to confirm this hypothesis. Although EECP is not currently cleared by the FDA for the treatment of T2D, the potential is clear, and at Vasomedical, we are devoting more effort and resources toward researching the benefits of this treatment for this particular patient population.

Tales from the Road: Hospitalar 2013

After three days of exhibiting at the Hospitalar 2013 meeting in São Paulo, we are even more convinced that Brazil will be an excellent market for EECP Therapy!

At the exhibition, Vasomedical displayed and demonstrated its core technology, EECP Therapy, its Biox ambulatory monitoring products and its EZ series patient management products. Visiting physicians and healthcare professionals expressed particular interest in how EECP technology can help patients with cardiovascular disease as well as significantly reduce healthcare costs.

We met with attendees from across the globe who were extremely pleasant and welcoming to the Vasomedical team and our products. It was a great experience participating in this event and understanding how we can expand our presence in South America.

The icing on the cake: we are in the process of registering Vasomedical and Biox products for sale in Brazil, putting us in a great position to build relationships for the near future!

Make sure to stay tuned for more tales from around the globe as we continue to showcase and educate the healthcare industry about EECP Therapy technology and our other offerings.

Next stop: New York, NY!

Tales from the Road: Africa Health Exhibition and Congress 2013

This week, we have been showcasing our technology at Africa Health Exhibition and Congress 2013 in Johannesburg, South Africa.

Reminiscent of when we first introduced EECP Therapy to the U.S. market in1995 at medical shows, the response of attendees at the South African Healthcare meeting this week was met by a variety of responses – from surprise to excitement. Many attendees were surprised to see such a well-documented treatment for the first time. They asked:  why have we never heard of this before?!

Physicians, nurses, hospital administrators and government officials all were curious to check it out and learn more about the technology and its benefits. They spent time with us in our booth to watch demonstrations and listen to our presentations to learn for the first time what this technology was all about and the life-changing impact it can have for those with heart conditions.

Attendees were also very interested in our Biox ECG Holter and ambulatory blood pressure monitors as well as our patient management products.

We met with attendees from across the globe including South Africa, Botswana, Mozambique, Zimbabwe, Namibia, Egypt, Algeria and the UAE. We believe that the reception of our products and the relationships we established will help us reach our goal of expanding sales in the African region.

Stay tuned for more tales from around the world as we continue to showcase and educate EECP Therapy technology and our other offerings. Next stop: Sao Paulo, Brazil!

ADVANCE for Nurses: The EECP Therapy Approach

As EECP Therapy gains more awareness in the U.S. and abroad, we are always excited to hear from advocates for this treatment.  Most recently, we are pleased about the increasing support for EECP from the nursing community.

Last week, ADVANCE for Nurses highlighted how EECP Therapy can treat patients with persistent angina symptoms, even after multiple traditional revascularization treatments have failed.  By exploring the many benefits of EECP Therapy, the article reinforced that EECP Therapy should be a go-to treatment option for patients with angina, as many of the costly invasive procedures can be ineffective.

To provide a medical professional’s point of view on the treatment, the article also featured the experiences of a registered nurse who has worked with EECP Therapy.

Sandy Muth, RN, cardiovascular diagnostics at Ohio State University Heart Center of Bellefontaine said: “We’ve seen a lot of improvement in our patients with EECP therapy. Several of them have requested repeat therapy due to the benefits it provided them. It is very rewarding to hear how their quality of life improves with treatment.”

We hope that this feature will encourage more nurses to advocate for EECP Therapy and in turn, offer EECP as a treatment option to more patients in the future. As always, feel free to email us at ajiang@vasomedical.com if you have any questions or comments.

Read the full story here.